Advanced Biomed Inc. (ADVB)

Nasdaq: ADVB · Services-Medical Laboratories · Reno, NV · filing with the SEC since 2022

Full chart Alerts Compare

Grade4.7

◀ Past 3.4● Present 6.0▶ Future 4.4

4 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Advanced Biomed Inc.

Nine metrics read from its own filings, by tense

Headline grade

4.7/10

◀ Past3.430% of the headline

● Present6.040% of the headline

▶ Future4.430% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 5 read as filed from the record and 4 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.4/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

1.3/10

Has it survived what it has been through?

5 warning events since 2022; the latest 2026-09-28.

weight 33% of this tense · 13th percentile among 27 sector filers · read for itself

From the record

Advanced Biomed Inc.'s filings since 2022 show 5 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2026-01-21); a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2026-09-28) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

SI estimate

4.7/10

What has it actually done, year after year?

SI estimate 4.7/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 23 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate: Fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 23 members with one.
What the record cannot read: Fewer than three filed years of revenue on file.
How it was reasoned: family median, 23 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Advanced Biomed Inc.'s track record is put at 4.7 of 10 with a confidence of 20 of 100, because fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 23 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Shareholder treatment

as filed

3.8/10

How has it treated the people who own it?

Share count grew 11.9% a year. 0% of cash flow returned. Insiders: 0 sales, 0 purchases.

weight 22% of this tense · 38th percentile among 9 sector filers · read for its shareholders

From the record

Over the 2 fiscal years to 2026-06-30, Advanced Biomed Inc.'s diluted share count grew about 11.9% a year, and dividends and buybacks returned about 0% of its net income over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

What it rests on

the share count over the yearsbottom 39% of its family
cash returned against operating cash flowbottom 36% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

● Present

What are they doing right now?

6.0/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

7.0/10

Is it financially healthy right now?

ROE 54%: 54¢ of profit per shareholder dollar. Leverage 11%: owes 11¢ per asset dollar.

weight 33% of this tense · 70th percentile among 25 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2026-06-30, Advanced Biomed Inc. earned about 54 cents of profit for every dollar of shareholders' money. Leverage: it owed about 11 cents per dollar of assets, and net share issuance: its share count grew 22.1% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 17% of its family
return on equitytop 2% of its family
the share count against the year beforebottom 30% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

5.2/10

How strong is its position in its industry?

top 48% of 24 in its family; net margin 5231.3%.

weight 45% of this tense · 52nd percentile among 24 sector filers · read for its customers

From the record

Advanced Biomed Inc.'s standing among 24 graded names in its industry family: revenue of $128 thousand in fiscal 2026 ranks in the bottom 11% by size; a net margin of 5231.3% ranks in the top 6% (its annual reports).

What it rests on

revenue against the family$127,637bottom 11% of its family
net margin5231.3%top 6% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.9/10

What are the people in charge doing?

SI estimate 5.9/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 20 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: No officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 20 members with one.
What the record cannot read: No officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read.
How it was reasoned: family median, 20 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Advanced Biomed Inc.'s leadership is put at 5.9 of 10 with a confidence of 20 of 100, because no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 20 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

4.4/1030% of the headline grade · 1 of 3 filed, 2 estimated

Room to expand

as filed

2.2/10

How much room does it have to grow?

bottom 22% of 24 in its family for room to expand.

weight 22% of this tense · 22nd percentile among 24 sector filers · read for itself

From the record

Advanced Biomed Inc.'s room to grow, from the newest filed statements (fiscal 2026): cash of $386 thousand against no long-term debt tagged leaves 2.8% of its assets as net cash, bottom 33% of its family; cash from operations less capital spending is -1525.4% of revenue (bottom 10%) (its annual report).

What it rests on

cash less debt against assets2.8%bottom 33% of its family
cash from operations less capital spending against revenue-1525.4%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

SI estimate

5.3/10

What could actually drive growth from here?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 23 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 23 members with one.
What the record cannot read: The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending.
How it was reasoned: family median, 23 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Advanced Biomed Inc.'s growth drivers is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 23 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Expectations vs reality

SI estimate

4.7/10

Did its newest year beat what its own record pointed to?

SI estimate 4.7/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 20 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 20 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 20 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Advanced Biomed Inc.'s expectations vs reality is put at 4.7 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 20 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton ADVB · research, not advice